Skip to main content

Table 1 Clinicopathological characteristics of PCa patients treated with RP before and after PSM

From: Metabolic syndrome and its components predict the biochemical recurrence and adverse pathological features of patients following radical prostatectomy: a propensity score matching study

Characteristics

All patients (n = 525)

Propensity matched patients (n = 254)

MetS (n = 136)

Non-MetS (n = 389)

P value

MetS (n = 127)

Non-MetS (n = 127)

P value

Age (years), median (IQR)

68 (64–74)

70 (65–75)

0.083

69 (65–75)

71 (67–75)

0.099

BMI (kg/m2), n (%)

  

 < 0.001

  

 < 0.001

  < 25

23 (16.9%)

258 (66.3%)

 

23 (18.1%)

82 (64.6%)

 

  ≥ 25

113 (83.1%)

131 (33.7%)

 

104 (81.9%)

45 (35.4%)

 

Hypertension, n (%)

  

 < 0.001

  

1.000

 No

18 (13.2%)

252 (64.8%)

 

18 (14.2%)

18 (14.2%)

 

 Yes

118 (86.8%)

137 (35.2%)

 

109 (85.8%)

109 (85.8%)

 

Hyperglycemia, n (%)

  

 < 0.001

  

 < 0.001

 No

48 (35.3%)

325 (83.5%)

 

41 (32.3%)

106 (83.5%)

 

 Yes

88 (64.7%)

64 (16.5%)

 

86 (67.7%)

21 (16.5%)

 

Hypertriglyceridemia, n (%)

  

 < 0.001

  

 < 0.001

 No

47 (34.6%)

330 (84.8%)

 

45 (35.4%)

109 (85.8%)

 

 Yes

89 (65.4%)

59 (15.2%)

 

82 (64.6%)

18 (14.2%)

 

Low HDL-C, n (%)

  

 < 0.001

  

 < 0.001

 No

88 (64.7%)

345 (88.7%)

 

80 (63.0%)

118 (92.9%)

 

 Yes

48 (35.3%)

44 (11.3%)

 

47 (37.0%)

9 (7.1%)

 

PPC (%), median (IQR)

41.7 (23.1–66.7)

41.7 (24.1–61.5)

0.447

41.7 (23.1–66.7)

41.7 (23.1–61.5)

0.601

Preoperative PSA (ng/mL), n (%)

  

0.294

  

0.677

  < 20

94 (69.1%)

287 (73.8%)

 

89 (70.1%)

92 (72.4%)

 

  ≥ 20

42 (30.9%)

102 (26.2%)

 

38 (29.9%)

35 (27.6%)

 

Pathologic T Stage, n (%)

  

0.070

  

0.575

  ≤ T2c

69 (50.7%)

224 (57.6%)

 

68 (53.5%)

76 (59.8%)

 

 T3a

47 (34.6%)

95 (24.4%)

 

39 (30.7%)

35 (27.6%)

 

  ≥ T3b

20 (14.7%)

70 (18.0%)

 

20 (15.7%)

16 (12.6%)

 

Lymph node Status, n (%)

  

0.979

  

0.848

 N0/Nx

117 (86.0%)

335 (86.1%)

 

111 (87.4%)

112 (88.2%)

 

 N + 

19 (14.0%)

54 (13.9%)

 

16 (12.6%)

15 (11.8%)

 

Pathologic Gleason score, n (%)

  

0.692

  

0.296

  ≤ 3 + 4

45 (33.1%)

136 (35.0%)

 

42 (33.1%)

50 (39.4%)

 

  ≥ 4 + 3

91 (66.9%)

253 (65.0%)

 

85 (66.9%)

77 (60.6%)

 

Surgical margin, n (%)

  

0.414

  

0.609

 Negative

81 (59.6%)

247 (63.5%)

 

74 (58.3%)

78 (61.4%)

 

 Positive

55 (40.4%)

142 (36.5%)

 

53 (41.7%)

49 (38.6%)

 

ECE, n (%)

  

0.180

  

0.310

 Absent

70 (51.5%)

226 (58.1%)

 

69 (54.3%)

77 (60.6%)

 

 Present

66 (48.5%)

163 (41.9%)

 

58 (45.7%)

50 (39.4%)

 

SVI, n (%)

  

0.307

  

0.338

 Absent

118 (86.8%)

323 (83.0%)

 

109 (85.8%)

114 (89.8%)

 

 Present

18 (13.2%)

66 (17.0%)

 

18 (14.2%)

13 (10.2%)

 
  1. BMI body mass index, ECE extra-capsular extension, HDL-C high density lipoprotein cholesterol, IQR interquartile range, MetS metabolic syndrome, PCa prostate cancer, PPC percentage of positive biopsy cores, PSA prostate specific antigen, PSM propensity score matching, RP radical prostatectomy, SVI seminal vesicle invasion
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us